Document is current
Any future updates will be listed below
-
Authors
Beese, Sophie E.
Price, Malcolm J.
Tomlinson, Claire
Sharma, Pawana
Harris, Isobel M.
Adriano, Ada
Quinn, Lauren M.
Gada, Ritu
Horgan, Thomas J.
Maggs, Fiona
Burrows, Martin
Nirantharakumar, Krishnarajah
Thomas, G. Neil
Andrews, Robert C.
Moore, David J.
Narendran, Parth
-
Funding
Funding for this research was provided by:
National Institute for Health and Care Research (PB-PG-0317-20046, PB-PG-0317-20046, PB-PG-0317-20046, PB-PG-0317-20046, PB-PG-0317-20046, PB-PG-0317-20046, PB-PG-0317-20046, PB-PG-0317-20046, PB-PG-0317-20046, PB-PG-0317-20046, PB-PG-0317-20046, PB-PG-0317-20046)
Breakthrough T1D (201311771, 201311771, 201311771, 201311771, 201311771)
- License Information
-
More Information
Article History
Received: 14 March 2025
Accepted: 10 June 2025
First Online: 1 July 2025
Declarations
:
: Not applicable.
: Not applicable.
: Dr. D J Moore - Early parts of this research stem from a research grant from the UK NIHR Research for Patient Benefit programme ((2018-2019) Ref: PB-PG-0317-20046; Co-Principal Investigator Dr. M J Price - Early parts of this research stem from a research grant from the UK NIHR Research for Patient Benefit programme ((2018-2019) Ref: PB-PG-0317-20046; Co-Investigator Prof P Narendran – Consulting fees for advisory board for medical devices for Abbott in 2022 and 2023 (not therapy related to current review) and OmniPod 5 in 2022. Payment received for lecture delivered on diabetes for Lilly Diabetes. Dr. R C Andrews – Payment received for delivering teaching sessions on type 1 diabetes and exercise for Eli Lilly and AstraZeneca. Early parts of this research stem from a research grant from the UK NIHR Research for Patient Benefit programme ((2018-2019) Ref: PB-PG-0317-20046 Ms. P Sharma - PS is a former employee of University of Birmingham and currently works for ICON plc, a healthcare consulting company funded by different pharmaceutical companies. The work on this manuscript is not related to her current role in ICON. Ms. A Adriano – AA worked at University of Birmingham at the time of the work being undertaken. Since contributing to the research in the manuscript, AA has since gone on to work for MSD (UK) Limited, London, UK who is the Marketing Authorisation Holder of the following medicinal products: ertugliflozin (Steglatro®) and sitagliptin (Januvia®, Janumet®), both indicated for the treatment of adults with type 2 diabetes mellitus as a monotherapy or in addition to other medicinal products for the treatment of diabetes. These drugs are not relevant to or mentioned in this manuscript. No other conflicts were identified.
